Solid Tumors (Phase 1)
Conditions
Brief summary
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360-Na when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.
Interventions
DRUGHSK42360-Na
Oral administration
Sponsors
Haisco Pharmaceutical Group Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years#Male and female patients, at time of signing informed consent form (ICF). 2. ECOG performance status 0-1, or KPS (Karnofsky Performance Status) Score≥70. 3. Life expectancy ≥ 3 months. 4. Patients with locally advanced or metastatic solid tumors confirmed by histology or cytology, who have failed standard treatment (disease progression after treatment or intolerable treatment); patients who have previously received BRAF and/or MEK inhibitor therapy are allowed to be included in this study. 5. Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360-Na. 6. Patients will provide blood or tumor sample according to their own willingness. 7. Measurable or non-measurable disease by RECIST 1.1 or RANO criteria. 8. Brain metastasis patients with inactive CNS lesions; Original intracranial tumor patient with inactive CNS lesions, or patients treated with ≤4mg/day corticosteroid and without convulsion for ≥2 weeks. 9. Adequate hematologic, hepatic, and renal function. 10. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose.
Exclusion criteria
1. malignant tumor within 2 years, with the exception of cutaneous squamous cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma, or other tumors with low malignancy. 2. Uncontrollable pleural effusion, ascites, or pericardial effusion per protocol. 3. Treatment with any of the following: Prior treatment with anti-tumor drug within 4 weeks or approximately 5 × t1/2 prior to the first dose of HSK42360-Na, whichever is shorter; Prior treatment with nitrosourea or mitomycin C within 6 weeks prior to the first dose of HSK42360-Na; Prior treatment with palliative radiotherapy or anti-tumor herbs within 2 weeks prior to the first dose of HSK42360-Na; Prior treatment with radiotherapy, electric field therapy, or other anti-tumor therapies within 4 weeks prior to the first dose of HSK42360-Na. 4. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia, dermal toxicity, and other toxicity considering no safety risks by investigator. 5. Any disease which would preclude drug absorption, metabolism or pharmacokinetics, e.g. active peptic ulcer or chronic gastroesophageal reflux disease. 6. Patients who have clinically significant or uncontrolled cardiac disease, include: QTc interval ≥ 450(male)/470(female) msec; any clinically significant arrhythmia; left ventricular ejection fraction \< 50%; myocardial infarction, unstable angina, or class III/IV cardiac failure by the NYHA that occurred within 6 months prior to the first dose of HSK42360-Na. 7. Any thromboembolic events within 6 months prior to the first dose of HSK42360-Na; any familial or acquired thrombophilia. 8. Uncontrolled hypertension (systolic pressure≥160mmHg, or diastolic pressure≥100mmHg), diabetes (fasting blood-glucose≥10mmol/L), seizures, chronic obstructive pulmonary disease (COPD), interstitial pneumonia, pulmonary interstitial fibrosis, Parkinson's disease, active bleeding, or systemic active infection. 9. Any unstable systemic disease, e.g. severe metabolic disease: liver cirrhosis, renal failure, or uremia. 10. Treatment with inhibitors/inducers for CYP3A4, or substrates of CYP3A4, CYP2C9, CYP2C8, OATP1B1, OATP1B3, OAT1, OAT3, P-gp or BCRP within 14 days or approximately 5 × t1/2 prior to the first dose of HSK42360-Na, whichever is shorter. 11. Patient with cognitive dysfunction, or history of mental illness, other uncontrolled comorbidities, alcohol dependence, hormone dependence or drug abuse. 12. Autologous transplantation surgery within 3 months prior to the first dose of HSK42360-Na; Allogeneic transplantation, or stem-cell Transplant surgery within 6 months prior to the first dose of HSK42360-Na; Major surgery or significant traumatic injury occurring within 4 weeks prior to the first dose of HSK42360-Na. 13. Patient with a history of immunodeficiency, including HIV positive, or other acquired/congenital immunodeficiency diseases. 14. Any disease of the eyes \> CTCAE v5.0 Grade 1. 15. Patient with active hepatitis B or hepatitis C. 16. Patient with active syphilis infection. 17. Allergic to any HSK42360-Na active constituent or ingredients. 18. Participate in other clinical trials within 4 weeks prior to the first dose of HSK42360-Na. 19. Positive pregnancy test, or breastfeeding. 20. Any other circumstances that would, in the investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MTD | Up to approximately 52 months | MTD determination: dose limiting toxicity (DLT) rate |
| DLTs | Up to approximately 52 months | Incidence of dose-limiting toxicities (DLTs) at Cycle 0 and Cycle1 |
| AEs | Up to approximately 52 months | Rate and severity of adverse events of HSK42360-Na as monotherapy |
| RP2D | Up to approximately 52 months | The RP2D is determined based on multiple parameters |
| ECOG Performance Status Scale | Up to approximately 52 months | Change of the grade as a part of HSK43260 safety data. Scores range from 0 to 5, with lower scores indicating better patient performance status. |
| Karnofsky Performance Scale, KPS | Up to approximately 52 months | Change of the grade as a part of HSK43260 safety data. Scores range from 0 to 100, with higher scores indicating better patient performance status. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) | Up to approximately 52 months | ORR, defined as the proportion of patients who experience a best response of confirmed CR or PR according to RECIST 1.1/RANO |
| Disease control rate (DCR) | Up to approximately 52 months | DCR, defined as the proportion of patients who experience a best response of CR, PR, or stable disease (SD) according to RECIST 1.1 |
| Duration of response (DOR) | Up to approximately 52 months | DOR, defined as the time from first documented response of complete response (CR) or partial response (PR) to the date of first documented progressive disease or death due to any cause, whichever occurs first |
| Progression free survival (PFS) | Up to approximately 52 months | PFS, defined as the time frocease or death due to any cause, whichever occurs first |
| Overall survival (OS) | Up to approximately 52 months | OS, defined as the time from the first dose of HSK42360-Na until the date of death due to any cause |
| Area under the curve (AUC) of HSK42360-Na | Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days) | — |
| maximum plasma concentration (Cmax) of HSK42360-Na | Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days) | — |
| half-life (t1/2) of HSK42360-Na | Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days) | — |
| Tmax(Time to maximum plasma concentration) of HSK42360-Na | Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days) | — |
Countries
China
Contacts
CONTACTLin Shen
Outcome results
None listed